Comparison of the activity of meropenem with that of other agents in the treatment of intraabdominal, obstetric/gynecologic, and skin and soft tissue infections

Donald Pitkin, Waheed Sheikh, Samuel Wilson, David Hemsell, Ronald Nichols, Harriette Nadler, Michael Dowzicky

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Meropenem, a new carbapenem with improved stability in the presence of human dehydropeptidase-I[1], was evaluated in three prospective, multicenter, randomized, controlled clinical trials in North America. We compared the in vitro activity of meropenem and conventional antimicrobial agents for the treatment of intraabdominal, obstetric/gynecologic, and skin or soft tissue infections as well as the responses of pathogens to all of these agents. The trials of the drug for intraabdominal infection were double blind, and those for the obstetric/gynecologic and soft tissue infections were open labeled. Overall, MICs of meropenem for pathogens were lower, and the pathogen response rates were at least comparable to those for the following comparative agents: clindamycin plus tobramycin (for intraabdominal infections); clindamycin plus gentamicin (for obstetric/gynecologic infections); and imipenem and cilastatin (for skin or soft tissue infections). Meropenem has high in vitro potency and covers a broad spectrum of anaerobic and aerobic pathogens.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume20
Issue numberSUPPL. 2
StatePublished - Jun 1995

Fingerprint

meropenem
Soft Tissue Infections
Obstetrics
Intraabdominal Infections
Skin
Clindamycin
dipeptidase 1
Tobramycin
Carbapenems
North America
Anti-Infective Agents
Gentamicins
Randomized Controlled Trials
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology

Cite this

Comparison of the activity of meropenem with that of other agents in the treatment of intraabdominal, obstetric/gynecologic, and skin and soft tissue infections. / Pitkin, Donald; Sheikh, Waheed; Wilson, Samuel; Hemsell, David; Nichols, Ronald; Nadler, Harriette; Dowzicky, Michael.

In: Clinical Infectious Diseases, Vol. 20, No. SUPPL. 2, 06.1995.

Research output: Contribution to journalArticle

Pitkin, Donald ; Sheikh, Waheed ; Wilson, Samuel ; Hemsell, David ; Nichols, Ronald ; Nadler, Harriette ; Dowzicky, Michael. / Comparison of the activity of meropenem with that of other agents in the treatment of intraabdominal, obstetric/gynecologic, and skin and soft tissue infections. In: Clinical Infectious Diseases. 1995 ; Vol. 20, No. SUPPL. 2.
@article{975c565f61b84dffbdeab84440c6b115,
title = "Comparison of the activity of meropenem with that of other agents in the treatment of intraabdominal, obstetric/gynecologic, and skin and soft tissue infections",
abstract = "Meropenem, a new carbapenem with improved stability in the presence of human dehydropeptidase-I[1], was evaluated in three prospective, multicenter, randomized, controlled clinical trials in North America. We compared the in vitro activity of meropenem and conventional antimicrobial agents for the treatment of intraabdominal, obstetric/gynecologic, and skin or soft tissue infections as well as the responses of pathogens to all of these agents. The trials of the drug for intraabdominal infection were double blind, and those for the obstetric/gynecologic and soft tissue infections were open labeled. Overall, MICs of meropenem for pathogens were lower, and the pathogen response rates were at least comparable to those for the following comparative agents: clindamycin plus tobramycin (for intraabdominal infections); clindamycin plus gentamicin (for obstetric/gynecologic infections); and imipenem and cilastatin (for skin or soft tissue infections). Meropenem has high in vitro potency and covers a broad spectrum of anaerobic and aerobic pathogens.",
author = "Donald Pitkin and Waheed Sheikh and Samuel Wilson and David Hemsell and Ronald Nichols and Harriette Nadler and Michael Dowzicky",
year = "1995",
month = "6",
language = "English (US)",
volume = "20",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Comparison of the activity of meropenem with that of other agents in the treatment of intraabdominal, obstetric/gynecologic, and skin and soft tissue infections

AU - Pitkin, Donald

AU - Sheikh, Waheed

AU - Wilson, Samuel

AU - Hemsell, David

AU - Nichols, Ronald

AU - Nadler, Harriette

AU - Dowzicky, Michael

PY - 1995/6

Y1 - 1995/6

N2 - Meropenem, a new carbapenem with improved stability in the presence of human dehydropeptidase-I[1], was evaluated in three prospective, multicenter, randomized, controlled clinical trials in North America. We compared the in vitro activity of meropenem and conventional antimicrobial agents for the treatment of intraabdominal, obstetric/gynecologic, and skin or soft tissue infections as well as the responses of pathogens to all of these agents. The trials of the drug for intraabdominal infection were double blind, and those for the obstetric/gynecologic and soft tissue infections were open labeled. Overall, MICs of meropenem for pathogens were lower, and the pathogen response rates were at least comparable to those for the following comparative agents: clindamycin plus tobramycin (for intraabdominal infections); clindamycin plus gentamicin (for obstetric/gynecologic infections); and imipenem and cilastatin (for skin or soft tissue infections). Meropenem has high in vitro potency and covers a broad spectrum of anaerobic and aerobic pathogens.

AB - Meropenem, a new carbapenem with improved stability in the presence of human dehydropeptidase-I[1], was evaluated in three prospective, multicenter, randomized, controlled clinical trials in North America. We compared the in vitro activity of meropenem and conventional antimicrobial agents for the treatment of intraabdominal, obstetric/gynecologic, and skin or soft tissue infections as well as the responses of pathogens to all of these agents. The trials of the drug for intraabdominal infection were double blind, and those for the obstetric/gynecologic and soft tissue infections were open labeled. Overall, MICs of meropenem for pathogens were lower, and the pathogen response rates were at least comparable to those for the following comparative agents: clindamycin plus tobramycin (for intraabdominal infections); clindamycin plus gentamicin (for obstetric/gynecologic infections); and imipenem and cilastatin (for skin or soft tissue infections). Meropenem has high in vitro potency and covers a broad spectrum of anaerobic and aerobic pathogens.

UR - http://www.scopus.com/inward/record.url?scp=0028997775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028997775&partnerID=8YFLogxK

M3 - Article

C2 - 7548602

AN - SCOPUS:0028997775

VL - 20

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 2

ER -